mk-1775 and Adenocarcinoma

mk-1775 has been researched along with Adenocarcinoma* in 2 studies

Trials

1 trial(s) available for mk-1775 and Adenocarcinoma

Article	Year
AZD1775 plus chemoradiotherapy for pancreatic cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:9 Topics: Adenocarcinoma; Chemoradiotherapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Pancreatic Neoplasms; Progression-Free Survival; Pyrazoles; Pyrimidinones	2019

Other Studies

1 other study(ies) available for mk-1775 and Adenocarcinoma

Article	Year
Targeting WEE1 in Pancreatic Cancer. Cancer discovery, 2019, Volume: 9, Issue:10 According to results from a phase I/II trial, the investigational WEE1 inhibitor adavosertib combined with gemcitabine and radiation is well tolerated and may benefit patients with locally advanced pancreatic adenocarcinoma by increasing both systemic and local disease control. Topics: Adenocarcinoma; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones	2019

Article

Year

Targeting WEE1 in Pancreatic Cancer.

Cancer discovery, 2019, Volume: 9, Issue:10

According to results from a phase I/II trial, the investigational WEE1 inhibitor adavosertib combined with gemcitabine and radiation is well tolerated and may benefit patients with locally advanced pancreatic adenocarcinoma by increasing both systemic and local disease control.

Topics: Adenocarcinoma; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones

2019